0L49.L - SCYNEXIS, Inc.

LSE - LSE Delayed price. Currency in USD


1 Evertrust Plaza
13th Floor
Jersey City, NJ 07302-6548
United States
201 884 5485

Full-time employees36

Key executives

NameTitlePayExercisedYear born
Mr. David Gonzalez Angulo M.D.CEO, Pres & Director631.69kN/A1965
Mr. Scott Sukenick J.D.Chief Legal Officer & Corp. Sec.542.05kN/A1978
Mr. Ivor Macleod CPA, M.B.A.Chief Financial OfficerN/AN/A1961
Debbie EtchisonExec. Director of CommunicationsN/AN/AN/A
Ms. Daniella GiganteVP of HRN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Corporate governance

SCYNEXIS, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.